Infliximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, Applications (Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others), Distribution Channel, Region And Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Infliximab Biosimilar Market Snapshot Chapter 4. Global Infliximab Biosimilar Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034 4.8. Global Infliximab Biosimilar Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034 4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024) 4.10. Use/impact of AI on Infliximab Biosimilar Market Industry Trends Chapter 5. Infliximab Biosimilar Market Segmentation 1: By Brand, Estimates & Trend Analysis 5.1. Market Share by Brand, 2024 & 2034 5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Brand: 5.2.1. Avsola (infliximab-axxq) 5.2.2. Flixabi (SB2) 5.2.3. Inflectra (infliximab-dyyb) 5.2.4. Ixifi (infliximab-qbtx) 5.2.5. Remicade 5.2.6. Zessly 5.2.7. Infimab (BOW015) 5.2.8. NI-071 5.2.9. Infliximab BS 5.2.10. CMAB008 5.2.11. Others (Products approved in developing countries & pipeline products) Chapter 6. Infliximab Biosimilar Market Segmentation 2: By Application, Estimates & Trend Analysis 6.1. Market Share by Application, 2024 & 2034 6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application: 6.2.1. Crohn's Disease 6.2.2. Psoriatic Arthritis 6.2.3. Rheumatoid Arthritis 6.2.4. Ulcerative Colitis 6.2.5. Ankylosing Spondylitis 6.2.6. Plaque Psoriasis and others Chapter 7. Infliximab Biosimilar Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis 7.1. Market Share by Distribution Channel, 2024 & 2034 7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel: 7.2.1. Hospital Pharmacy 7.2.2. Online Pharmacy 7.2.3. Retail Pharmacy 7.2.4. Other Direct Distribution Channels Chapter 8. Infliximab Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis 8.1. Global Infliximab Biosimilar Market, Regional Snapshot 2024 & 2034 8.2. North America 8.2.1. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034 8.2.1.1. US 8.2.1.2. Canada 8.2.2. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034 8.2.3. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034 8.2.4. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034 8.3. Europe 8.3.1. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034 8.3.1.1. Germany 8.3.1.2. U.K. 8.3.1.3. France 8.3.1.4. Italy 8.3.1.5. Spain 8.3.1.6. Rest of Europe 8.3.2. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034 8.3.3. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034 8.3.4. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034 8.4. Asia Pacific 8.4.1. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034 8.4.1.1. India 8.4.1.2. China 8.4.1.3. Japan 8.4.1.4. Australia 8.4.1.5. South Korea 8.4.1.6. Hong Kong 8.4.1.7. Southeast Asia 8.4.1.8. Rest of Asia Pacific 8.4.2. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034 8.4.3. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034 8.4.4. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034 8.5. Latin America 8.5.1. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034 8.5.1.1. Brazil 8.5.1.2. Mexico 8.5.1.3. Rest of Latin America 8.5.2. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034 8.5.3. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034 8.5.4. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034 8.6. Middle East & Africa 8.6.1. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034 8.6.1.1. GCC Countries 8.6.1.2. Israel 8.6.1.3. South Africa 8.6.1.4. Rest of Middle East and Africa 8.6.2. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034 8.6.3. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034 8.6.4. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034 Chapter 9. Competitive Landscape 9.1. Major Mergers and Acquisitions/Strategic Alliances 9.2. Company Profiles 9.2.1. Amgen 9.2.1.1. Business Overview 9.2.1.2. Key Product/Service 9.2.1.3. Financial Performance 9.2.1.4. Geographical Presence 9.2.1.5. Recent Developments with Business Strategy 9.2.2. Samsung Bioepis 9.2.3. Celltrion 9.2.4. Pfizer 9.2.5. Johnson & Johnson 9.2.6. Sandoz (Novartis division) 9.2.7. Epirus Biopharmaceuticals 9.2.8. Nichi-Iko Pharmaceutical 9.2.9. Mabpharm 9.2.10. Biogen 9.2.11. Merck (MSD) 9.2.12. Ranbaxy Laboratories (now Sun Pharma) 9.2.13. Sorrento Therapeutics (partner) 9.2.14. Other Prominent Players